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Introduction
Tumor-to-intracranial tumor metastasis is a known but rare 
phenomenon, with relatively limited representation in the 
literature (1). This scenario is most likely to be witnessed 
with indolent tumors being seeded by an aggressive or widely 
metastatic carcinoma (2). The most common intracranial 
tumors to receive distant metastases are meningiomas, 
with breast carcinoma being the most common donor (3). 
The incidence of this occurrence is likely underreported, 
given the limited ability to evaluate beyond histopathologic 
confirmation, the high threshold to pursue neurosurgical 
intervention in asymptomatic patients, and increasing 
survival times with modern systemic therapies (2). The 
significance or mechanism of this process is not completely 
understood. In this study, we present the following case of a 
56-year-old woman with an intracranial meningioma found 
to be seeded by previously-treated breast cancer primaries 
leading to the diagnosis of oligometastatic disease.
We present the following case in accordance with the 
CARE reporting checklist (available at http://dx.doi.
org/10.21037/cco-20-122) (4).
Case presentation
The authors are accountable for all aspects of the work in 
ensuring that questions related to the accuracy or integrity 
of any part of the work are appropriately investigated and 
resolved. All procedures performed in studies involving human 
participants were in accordance with the ethical standards of 
the institutional and/or national research committee(s) and 
with the Helsinki Declaration (as revised in 2013).
A 56-year-old female patient presented with left lower 
extremity weakness and focal motor seizures. Evaluation 
revealed bilateral diplopia for the preceding two months and 
headaches for the past week. Her past medical history was 
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remarkable for bilateral invasive lobular breast carcinoma, 
estrogen receptor (ER) and progesterone receptor (PR) 
positive, HER2-negative, both treated with surgery, 
chemotherapy, radiation, and hormonal therapy five years 
(right breast T3N1M0) and two years (left breast T1cN0M0) 
prior to presentation, respectively. Magnetic resonance 
imaging (MRI) of the brain revealed a large, extra-axial, 
homogenously-enhancing mass in the right middle cranial 
fossa, measuring 4.9 cm × 6.5 cm × 5.4 cm (Figure 1), with 
1.4 cm midline shift and mild bowing of the sphenoid cortex 
into the orbit, consistent with meningioma. The patient 
underwent image-guided craniotomy with access through 
the root of the right zygoma. The mass was devascularized, 
sharp resection performed with extensive cauterization of the 
surrounding dura, and postoperative computed tomography 
(CT) of the head suggestive of gross total resection.
Pathologic findings
The final pathology report of the resected neoplasm 
revealed a World Health Organization (WHO) grade I 
meningioma (Figure 2A) with a Ki-67 proliferation index of 
6.4%. Due to some morphologic overlap with schwannoma, 
confirmatory immunohistochemical stains were performed. 
Immunohistochemistry for S100 was negative, while EMA 
showed mild diffuse immunoreactivity supportive of the 
diagnosis of meningioma (Figure 2B). However, there 
were rare individual and small clusters of darker-staining 
epithelioid cells within the meningioma that were not 
otherwise appreciated on the original hematoxylin and eosin 
(H&E) stained sections (Figure 2C). By careful alignment 
of the EMA-stained cell clusters with the H&E-stained 
sections, small linear clusters could be identified that were 
morphologically consistent with lobular breast carcinoma. 
Breast markers GATA3 and GCDFP-mammaglobin (Figure 
2D,E) confirmed the presence of metastatic lobular breast 
carcinoma. Additional immunohistochemistry for breast 
markers showed these tumor cells were positive for ER and 
2+ HER2/Neu staining (Figure 2F). Dual in situ hybridization 
for HER2/Neu and PR staining were non-contributory 
due to the inability to reliably distinguish rare, scattered, 
breast carcinoma cells from meningioma cells, and diffuse 
meningioma PR positivity.
Adjuvant treatment and follow up
The patient was referred to radiation oncology for 
evaluation of adjuvant radiotherapy (RT) to the resection 
cavity. Given the presence of metastatic breast cancer, 
stereotactic body radiotherapy (SBRT) was recommended. 
MRI was obtained four months after resection, which 
revealed significant reduction in the resection cavity and 
a questionable, small residual meningeal nodularity in 
the posterior resection cavity on T1 post-gadolinium 
sequences. She was treated to a total dose of 30 Gy in 
five fractions using volumetric modulated arc therapy 
(VMAT) in three arcs, flattening-filter-free, prescribed to 
the 98.6% isodose line. She completed RT without acute 
toxicity, and subsequent complete resolution of presenting 
symptoms. PET scan one month after RT revealed a single, 
sclerotic, osseous lesion at L3, and she was referred to her 
medical oncologist and started on systemic therapy. MRI 
of the brain three and six months after RT revealed post-
treatment changes without evidence of recurrence (Figure 3). 
Repeat staging scans revealed no other areas of disease. 
She continued to be without intracranial recurrence and 
received systemic therapy until three years after RT, when 
she suffered a myocardial infarction and expired. A timeline 
of care received by the patient is available in Figure 4.
Figure 1 MRI brain at presentation. Preoperative T1-weighted 
post-gadolinium sequence MRI of the brain in the axial plane 
demonstrating a 4.9 cm × 6.5 cm × 5.4 cm homogenously-
enhancing, intracranial mass involving the right greater wing of 
the sphenoid with midline shift. 
Chinese Clinical Oncology, Vol 9, No 5 October 2020
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Figure 3 Post-treatment MRI brain. T1-weighted post-gadolinium 
sequence MRI of the brain six months post radiotherapy in the 
axial plane showing significant contraction of the surgical cavity, 
curvilinear enhancement, and stable meningeal enhancement along 
the craniotomy flap.
Figure 2 Meningioma pathology. Characteristic whorl pattern morphology of meningioma at 100× (A). EMA immunohistochemistry at 
400× demonstrating diffuse background staining for the meningioma, along with darker staining lobular breast carcinoma cells (B). Single-
file pattern on H&E within the meningioma suggestive of lobular breast carcinoma at 400× (C). Lobular breast carcinoma cells at 400× 
showing immune-reactive for GATA3 (D), GCDFP-Mammoglobulin (E), and HER2Neu (F).
Discussion
In the 1930s, tumor-to-tumor metastasis to meningioma was 
first recorded by Fried BM (5). Of the total cases reported 
since, over 70% involved meningiomas, of which nearly 
half involved breast cancer metastasis (6). The prevalence 
of this phenomenon is postulated to be partly from the 
overlapping epidemiology of patients with breast cancer and 
meningiomas (7). In addition, the Swedish Cancer Registry 
and the United States Surveillance, Epidemiology, and 
End Results Program (SEER) reported an increase in the 
diagnosis of meningiomas after diagnosis of primary breast 
cancer, although this is likely a manifestation of increased 
brain imaging (8). Meningiomas are mostly slow-growing, 
hypervascular intracranial tumors. Such characteristics 
increase the chances of meningeal seeding via hematogenous 
spread. They have high lipid and collagen contents and lack 
a reactive immune response against foreign bodies, creating 
an optimal seeding environment (2,9-11). These factors may 
explain why meningiomas are the most common benign 
intracranial tumor to accept distant metastases (12). 
The relatively increased affinity of metastatic breast 
carcinoma cells to meningiomas may also be attributed 
to facilitating receptor environments. Estrogen and 
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Figure 4 Timeline of events. Timeline of care received by the patient including relevant radiographic imaging, surgeries, and radiotherapies. 
MRI, magnetic resonance imaging; VMAT, volumetric modulated arc therapy; PET/CT, positron emission tomography/computed 
tomography; RT, radiotherapy.
progesterone receptors found on meningiomas are thought 
to be involved in cell-to-cell interactions with breast 
carcinoma cells (13). Furthermore, it has been suggested 
that breast cancer metastasis is mediated through the 
endothelial growth factor receptor (EGFR) family pathway. 
HER2-positive breast carcinoma in particular may develop 
metastases through HER3 receptor and neuregulin 1 
EGFRs (2,14). The HER3-receptor pathway plays a role in 
the growth of HER2-positive breast carcinoma cells while 
neuregulin 1 is believed to be upregulated on meningioma 
cells (14). These described pathways could be relevant for 
the mechanism of metastasis in the case presented.
The prognostic impact of tumor-to-tumor metastasis 
remains unclear. Unique to our case was the diagnosis 
of metastatic disease from meningioma resection and 
oligometastatic disease burden upon further work-up. Post-
surgical RT in the presented case demonstrated efficacy in 
local control. The patient continued to experience relief of 
symptoms following surgical resection and RT, and limited 
extracranial disease. This outcome is seemingly discordant to 
many of the similarly-reported cases. The majority of reviewed 
cases describing tumor-to-tumor metastasis from breast 
carcinoma to an intracranial meningioma report diffusely 
metastatic disease, worsening of presenting symptoms, poor 
local control with RT or systemic therapy, and eventual 
mortality, or do not mention outcomes (2,5,7,9-12,14). This 
is likely due to the early diagnosis of oligometastatic disease, 
rather than heavily pretreated, widely-metastatic disease, 
as in other reports. Given the constellation of factors that 
facilitate breast-to-meningioma metastases, and low resection 
rates of meningiomas among metastatic breast cancer 
patients, it is questionable if the prognostic significance, if 
any, will ever be elucidated. Patients with prior history of 
malignancy, especially breast cancer, who undergo resection 
of meningiomas warrant close pathologic examination, even 
without history of metastatic disease, as demonstrated by 
our case report. Further publications of similar cases should 
provide detailed documentation regarding clinical factors, 
pathology, extracranial disease status, and prior treatments to 
best characterize this phenomenon and factors associated with 
their occurrence.
Conclusions
In conclusion, we present a case of tumor-to-tumor metastasis 
from invasive lobular breast carcinoma to meningioma 
that resulted in the early diagnosis of oligometastatic, 
breast cancer. Careful pathologic examination of resected 
meningiomas in this patient group is warranted. Future 
reports should include detailed information regarding 
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patients, pathology, disease control, and treatment history.
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